## Page 1

FoodandChemicalToxicology74(2014)190–199
ContentslistsavailableatScienceDirect
Food and Chemical Toxicology
journal homepage: www.elsevier.com/locate/foodchemtox
A toxicological safety assessment of a standardized extract of
Sceletium tortuosum (Zembrin®) in rats
TimothyS.Murbacha,*,GáborHirkab,IlonaPasicsSzakonyinéb,NigelGerickec,
JohnR.Endresa
aAIBMRLifeSciences,Inc.,4117SouthMeridian,Puyallup,WA98373,USA
bToxi-CoopZrt.,Deresu.10/A,H-1124Budapest,Hungary
cHG&HPharmaceuticals(Pty)Ltd.,Bryanston2191,SouthAfrica
A R T I C L E I N F O A B S T R A C T
Articlehistory: Awell-characterizedstandardizedhydroethanolicextractofatraditionallyrecognizedmak(mild)variety
Received5May2014 ofSceletiumtortuosum,aSouthAfricanplantwithalonghistoryoftraditionalingestion,ismarketedunder
Accepted26September2014 thetradenameZembrin®asaningredientforuseinfunctionalfoodsanddietarysupplements.Itisstan-
Availableonline6October2014 dardizedtocontain0.35–0.45%totalalkaloids(mesembrenoneandmesembrenol≥60%,andmesembrine
<20%).A14-dayrepeatedoraltoxicitystudywasconductedat0,250,750,2500,and5000mg/kgbw/
Keywords:
day.A90-daysubchronicrepeatedoraltoxicitystudywasconductedat0,100,300,450,and600mg/kg
Sceletiumtortuosum
bw/day.BecauseS.tortuosumhasalonghistoryofhumanuseforrelievingstressandcalming,afunc-
Safetyassessment
tionalobservationbattery,includingspontaneouslocomotoractivitymeasuredusingLabMasterActiMot
Toxicity
Zembrin light-beamframessystem,wasemployed.Severalparameters,suchaslocomotion,rearingbehavior,spatial
Stress parameters,andturningbehaviorwereinvestigatedinthefinalweekofthestudy.Nomortalityor
Anxiolytic treatment-relatedadverseeffectswereobservedinmaleorfemaleCrl:(WI)BRWistarratsinthe14-or
90-daystudies.Inthe14-and90-daystudies,theNOAELswereconcludedas5000and600mg/kgbw/
d,respectively,thehighestdosegroupstested.
©2014TheAuthors.PublishedbyElsevierLtd.ThisisanopenaccessarticleundertheCCBY-NC-ND
license(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction theInternet,arebeingusedbyhealthyindividualstopromoteasense
ofwell-beingandtorelievestress(GerickeandViljoen,2008).
TheendemicSouthAfricansucculentplantSceletiumtortuosum Therehasbeenconsiderableresearchonthechemistryofthe
(L.)N.E.Br.hasanancientoralhistoryofuseasamasticatoryprep- alkaloidscontainedintheplant(GerickeandViljoen,2008).Awide
arationandhealthteabyindigenousSanandKhoipeople.Thefirst rangeofvariationofthealkaloidchemistryinwildSceletiumplants
writtenrecordoftheplantbeingusedbyindigenouspeople,ac- hasbeendescribed(Shikangaetal.,2012),indicatingthenecessi-
companied by a painting of the plant, is from the year 1685 ty of selecting naturally occurring and traditionally used plant
(Waterhouseetal.,1979).Tinctures(hydroethanolicextracts)ofthe chemotypes for commercial production and standardizing ex-
plantwerereportedtobeincommonusebycolonistsoftheCape tracts of these plants to both the total alkaloid content and the
ofGoodHope(Pappe,1868)andcanstillbepurchasedfromhealth alkaloidcompositioninordertohavehighqualitycommercialprod-
shops, pharmacies, and farm stalls in South Africa. Packages of ucts. The four major S.tortuosum alkaloids (mesembrine,
S.tortuosum tea bags, often in combination with Red Bush Tea mesembrenone,mesembrenol,andmesembranol)havebeenshown
(Aspalathuslinearis)orHoneybushtea(Cyclopiaspp.),aresoldinsu- invitrotobepermeableacrossporcineintestinal,sublingual,and
permarkets in South Africa. Over the last 15 years, increasing buccalmucosa(Shikangaetal.,2012).
numbers of Sceletium-based products, including teas, tinctures, No formal toxicological studies have been previously pub-
tablets,capsules,andrawpowderedplantmaterial,oftensoldover lishedonS.tortuosumoronextractsof S.tortuosum.Small-scale
short-termstudiesindogsandcatshavebeenreported(Hirabayashi
etal.,2002,2004)withnoadverseeffectsnotedafterdailyadmin-
istrationofdriedS.tortuosumplantmaterialfor6or7days.
Abbreviations:HPLC-DAD,high-performanceliquidchromatography-diodearray Thesafetyandtolerabilityoftwodoses(8mgand25mgonce
detector;SPF,specificpathogen-free. daily)ofS.tortuosumextract(Zembrin®)(equivalentto16mgand
* Correspondingauthor.AIBMRLifeSciences,4117SouthMeridian,Puyallup,WA
50mgdryplantmaterial,respectively)wasstudiedovera3-month
98373,USA.Tel.:+12532862888;fax:+12532862451.
E-mailaddress:tim@aibmr.com(T.S.Murbach). periodinarandomizeddouble-blindplacebo-controlledparallel-
http://dx.doi.org/10.1016/j.fct.2014.09.017
0278-6915/©2014TheAuthors.PublishedbyElsevierLtd.ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(http://creativecommons.org/licenses/by-nc-nd/
3.0/).

## Page 2

T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199 191
Table1
CompositionalanalysisofSceletiumtortuosumextract(Zembrin®).a
Analysis Result(%dryweight)
Moisture 6.01
Carbohydrates 52.23
Protein(nitrogenX6.25) 6.49
Fattyacids 3.84
Alkaloids 0.417
Totalminerals(ashcontent) 33.3
TOTAL 102.3b
Fig.1. StructuresofthefourmainmesembrinealkaloidsthatarequantifiedbyHPLC
Individualmineralanalysis Result(%dryweight) todefinethealkaloidcontentandcompositionoftheextractofSceletiumtortuosum
(Zembrin®).
Iron 0.015
Calcium 0.033
Sodium 2.71
Totaloxalates 12.9
fortotalalkaloidcontent,alkaloidcomposition,pesticideresidues,heavymetals,af-
Silicondioxide ≤2
latoxins,andmicrobiologytoensurecompliancewithfinishedproductspecifications.
Heavymetalstotal ≤10ppm Thefinalproduct–Zembrin®–isafood-grade,non-GMO,certifiedallergen-
Abbreviations:ppm,partspermillion. freeandBSE(containsnoanimalderivatives)freeproductthatisfullysoluble
a Analysesbasedoninternalmethods. in water and is standardized to an alkaloid content of 0.35–0.45% w/w
b Tableresultsarethemeanvaluesreportedfromfourseparateandindepen- (HPLC-DAD). The relative amounts of major alkaloids (HPLC-DAD) are:
dentanalysesofthevariousconstituents. mesembrenone+mesembrenol≥60%andmesembrine<20%.Fig.1showsthe
chemicalstructuresofthefouractivealkaloids.
Multiplecompositionalanalyseshaveidentifiedthemajorconstituents
ofZembrin®tobecarbohydrates,ash,protein,andfattyacids.Minorconstituents
groupstudy(n=37)(Nelletal.,2013).Thesafetyandtolerability
includealkaloidsandminerals.ThetypicalcompositionalanalysisisshowninTable1
variablesstudiedwerevitalsigns,physicalexamination,12-leadelec- above.
trocardiogram,laboratoryassessments(hematology,biochemistry,
andurinalysis),andtherecordingofadverseevents(AEs).Therewere 2.2. Studies
noapparentdifferencesinanyofthesafetyandtolerabilityparam-
etersstudied,andbothdosesoftheextractwerewell-tolerated. TheGLPanimalstudiesreportedbelowwereconductedincompliancewithin-
ternationallyacceptedguidelines:OECD407(14-daystudy)(OECD,2008)andOECD
Historical use and emerging preclinical and clinical evidence
408(90-daystudy)(OECD,1998)andUSFDARedbook2000,IV.C.3.a(14-daystudy)
suggest that there is potential for the standardized extract of (FDA,2003a)andIV.C.4.a(90-daystudy)(FDA,2003b).Careanduseofstudyanimals
S.tortuosum–Zembrin®–tobeusedinteasandasadietarysup- wasinaccordancewiththeNationalResearchCouncilGuideforCareandUseof
plementtoenhanceand/ormaintainhealthandwellnessinhealthy LaboratoryAnimals(NRC,2011)andincompliancewiththeprinciplesoftheHun-
peoplewantingtofeelcalmerandunderlessstress. garianAct2011CLVIII(modificationofHungarianAct1998XXVIII)regulatinganimal
protection.
Asapreludetofurtherdevelopment,thesafetyofZembrin®,a
Distilledwaterforparenteraladministrationwasusedasthecontrolandthe
well-characterized(seeTable1)extractof S.tortuosumstandard- vehicleforadministrationofthetestarticle.Thetestarticledoseswereprepared
ized to contain 0.35–0.45% total alkaloids (mesembrenone and bydissolvingZembrin®indistilledwatertoachieveconcentrationsof25,75,250,
mesembrenol ≥60%, and mesembrine <20%), has been formally and500mg/mL(14-daystudy)and10,30,45,and60mg/mL(90-daystudy)toprovide
aconstantdosingvolumeof10mL/kgbw.Doseswereprepareddaily,shortlybefore
studiedinvivoin14-dayand90-dayrepeatedoraltoxicitystudies
administration,duringthe14-daystudyandeitherdailyorwithin7daysofad-
inrats,reportedhereforthefirsttime. ministrationduringthe90-daystudyduetoresultsofstabilityanalysisindicating
thatZembrin®isstablewhendissolvedindistilledwaterovera10dayinterval.The
2. Materialssandmethods controlgroupreceivedthesamevolumeofthevehicleonly.Theconcentration,sta-
bility,andalkaloidconcentrationandcompositionofthedosingsolutionswas
independentlyverifiedanalyticallypriortobeginningthe14-daystudy,andcon-
2.1. Testarticle
centrationsofthedosingsolutionswereindependentlyverifiedanalyticallytwice
duringthe14-daystudyandthreetimesduringthe90-daystudy.Analysisofthe
ThetestarticlewasZembrin®(manufacturedbyPolifenolesNaturales,SL,Pol.
testarticlewasperformedinanon-GLPacademicanalyticallaboratoryexperi-
Ind.LasMajoreras,35240Ingenio,LasPalmas,SpainforHG&HPharmaceuticals(Pty)
encedinchromatographicquantitativeanalysisofmesembrine-alkaloidsusing
Ltd.,TheBraes,193BryanstonDrive,Bryanston2191,SouthAfrica),aproprietary
validatedanalyticalreferencecompounds.
standardized2:1hydroethanolicextractofthedriedleavesandstemsofS.tortuosum.
Specificpathogen-free(SPF)maleandfemaleCrl:(WI)BRWistarrats(Toxi-
Zembrin®wasprovidedforuseasthetestarticle(batchnumbersSCE0411-1605
Coop,Budapest,Hungary)wereutilizedinbothstudies.Theanimalswerehoused
andSCE0412-0901forthe14-and90-daystudies,respectively),alongwithspeci-
inindividualtypeIIpolypropylene/polycarbonatecageswithcertifiedlaboratorywood
fications,certificatesofanalysis,andmaterialsafetydatasheets,byHG&H
bedding(Lignocel®)(cagesandbeddingwerechangedonceaweek),at22±3°C,
Pharmaceuticals(Pty)Ltd.AbriefdescriptionofZembrin®anditsmanufacturing
30–70%relativehumidity,anda12-hourlight-darkcycle.Theanimalsreceivedssniff®
processisprovidedasfollows:
SMR/M-Z+Hcompletedietforratsandmiceandpotabletapwateradlibitum.The
AsdeclaredbyHG&HPharmaceuticals(Pty)Ltd,thesourceplantmaterialwas
healthstatusoftheanimalswascertifiedbythebreeder,andapre-experimental
cultivatedinSouthAfrica.Nophytochemicalswereusedduringtheproductionof
period(12-days,14-daystudy/15-days,90-daystudy)wasprovidedtoacclimatize
S.tortuosumrawmaterialfortheproductionofZembrin®andnonewereaddedduring
theanimals.
themanufacturingprocess.TheproductionfarmswheretheS.tortuosumsourcema-
terialforZembrin®wasgrownareGlobalGoodAgriculturalPractice(GAP)certified.
TheuseofpesticidesinthecultivationoftheS.tortuosumsourcematerialforZembrin® 2.2.1. Fourteen-dayrepeated-doseoraltoxicitystudyinrats
waslimitedandrestrictedtotheperiodofseedgermination.Duringgrowthand Thisdoserange-findingstudywascarriedoutinordertoevaluaterepeatedoral
afterdrying,samplesoftheharvestedanddriedplantsourcematerialweresent administration,overa14-dayperiod,ofthetestarticleinmaleandfemaleratsfor
tointernationallycertifiedanalyticallaboratoriestoensureconformitywithinter- abroadrangeofdosesinordertodetermineanoobservedadverseeffectlevel
nationalstandardsforpesticideresidues,heavymetals,aflatoxins,andmicrobiology (NOAEL)andtoprovidedatafortheselectionofthedosegroupsforthe90-dayre-
andexclusionofpathogenicbacteria,andtheplantidentitywasconfirmedbymac- peatedoraltoxicitystudy.
roscopiccharacteristics,qualitative(GC-MS),andquantitative(HPLC)methods. FiftymaleandfemaleSPFWistarrats,approximately7weeksoldandweigh-
Theabovegroundpartswereharvested,washed,andair-driedbeforesending ing231–255g(males)and168–204g(females)atthestartoftheexperimentalperiod,
toPolifenolesNaturales,SL(anEU-GMPcertifiedmanufacturerofplantextract)for werestratifiedbyweightandrandomlyassignedtofivegroupsoffiverats/sex/
extraction.Thedriedmaterialwasmilled,extractedwithwater–ethanol(purified groupforadministrationofZembrin®dosesof0(vehicle-control),250,750,2500,
water30%v/vandethanol70%v/v),filtered,distilledtoremoveresidualsolvent, and5000mg/kgbw/daybygavagefor14-days.
andconcentratedbeforespraydryingontoamaltodextrincarrierthatwasad- Theanimalswereobservedtwicedailyformortality.Generalcage-sideobser-
justedtoproducethespecifiedstandardizationofalkaloids.Aftertheextraction, vationsforclinicalsignsweremadetwiceduringtheacclimationperiodandonce
concentration,andstandardizationprocesses,eachlot(batch)ofZembrin®wastested dailyafteradministrationofthetestarticle,anddetailedclinicalobservationswere

## Page 3

192 T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199
Table2
Summaryofmeanbodyweightandmeanfoodintakedatainthe14-dayrepeatedoraltoxicitystudy.
Meanbodyweight(g) Initial(Day0) Midway(Day7) End(Day13)
Male
Control(N=5) 244.6±6.5 289.6±6.8 316.2±9.5
250mg/kgbw/day(N=5) 247.0±5.6 295.4±10.8 327.8±17.5
750mg/kgbw/day(N=5) 245.0±8.6 291.0±15.3 320.8±17.7
2500mg/kgbw/day(N=5) 244.4±8.4 292.0±16.0 319.2±14.5
5000mg/kgbw/day(N=5) 244.8±10.2 287.2±18.4 316.4±24.8
Female
Control(N=5) 183.6±9.5 202.6±9.7 213.6±13.0
250mg/kgbw/day(N=5) 188.4±10.9 211.8±24.3 232.2±26.5
750mg/kgbw/day(N=5) 185.4±11.0 208.4±11.0 222.0±15.2
2500mg/kgbw/day(N=5) 183.0±11.0 205.6±14.7 224.6±19.5
5000mg/kgbw/day(N=5) 181.4±6.9 208.6±4.5 225.6±5.9
Meanfoodconsumption(g/rat/day) Days0–3 Days3–7 Days7–10 Days10–13
Male
Control(N=5) 25.4±1.4 26.5±1.2 26.7±1.2 27.9±0.6
250mg/kgbw/day(N=5)(%Deviationfromcontrol) 26.1±1.5(3) 27.5±2.4(4) 25.6±1.7(−4) 28.3±1.7(2)
750mg/kgbw/day(N=5)(%Deviationfromcontrol) 25.7±1.7(1) 27.0±1.3(2) 24.7±2.2(−8) 27.2±1.6(−2)
2500mg/kgbw/day(N=5)(%Deviationfromcontrol) 25.1±1.4(−1) 26.2±1.6(−1) 25.1±2.2(−6) 27.2±1.3(−2)
5000mg/kgbw/day(N=5)(%Deviationfromcontrol) 23.4±3.1(−8) 25.6±2.8(−3) 24.0±2.7(−10) 26.6±2.8(−5)
Female
Control(N=5) 18.3±1.4 18.8±1.0 17.9±0.5 19.8±1.3
250mg/kgbw/day(N=5)(%Deviationfromcontrol) 19.7±3.3(8) 21.0±4.5(11) 19.9±4.9(11) 21.5±2.9(8)
750mg/kgbw/day(N=5)(%Deviationfromcontrol) 20.2±3.5(10) 19.9±1.0(6) 18.3±1.0(2) 20.8±1.6(5)
2500mg/kgbw/day(N=5)(%Deviationfromcontrol) 23.3±1.4(27) 19.5±2.1(4) 18.1±2.4(1) 21.3±2.4(8)
5000mg/kgbw/day(N=5)(%Deviationfromcontrol) 22.5±0.4(23) 20.9±1.5(11) 18.3±1.7(2) 21.9±2.9(11)
Meanbodyweightdatarepresentthemeanandthestandarddeviationatthebeginning,mid-waythrough,andendofthestudy.
Foodintakedatarepresentthemeanvalueperratperdayandpercentdeviationfromcontrolatthebeginning,mid-waythrough,andendofthestudy.
StatisticalsignificancewassetatP<0.05.
conductedtwiceweekly.Measurementsoffoodintakeandbodyweightwere thesensoryframe.Inthecagepositionedintotheframe,theX-axisrepresentedlength
conductedtwiceduringtheacclimationperiodandtwiceweeklyduringtheex- (54cm),theY-axisrepresenteddepth(29cm),andtheZ-axisrepresentedheight
perimentalperiod;bodyweightswerealsodeterminedimmediatelypriortosacrifice. (41cm).WithintheActiMotsystemframe,movementalongtheX-axiswasmoni-
Ophthalmologicalexaminationwascarriedoutpriortoandattheendoftheex- toredby16sensors(emitterandreceiverpairs)installedalongthelongsides(54cm)
perimentalperiod. andmovementalongtheY-axiswasmonitoredbyeightsensorsinstalledalongthe
Afteranovernightfast(approximately16hours)followingfinaladministra- shortsides(29cm),respectively,ofoneflatframe.MovementalongtheZ-axiswas
tionofthetestarticle,bloodsampleswerecollectedfromtheretroorbitalvenous monitoredby16sensorsinstalledalongthelongsides(54cm)ofasecondflatframe
plexusunderIsofluranCP®anesthesiaafterwhichtheanimalswereeuthanizedby paralleltoandabovetheX/Yflatframe(i.e.,theZ-axissensorarraywasparallelto
exsanguinationfromtheabdominalaorta.Bloodsampleswereanalyzedforhema- theX-axissensorarrayandnosensorswereinstalledintheshortsidesofthe“Z
tologicandclinicalchemistryparametersandgrosspathologicalexaminationsand level”frame).Thepositionoftheflatframecontainingthe“Zlevel”sensorarray
determinationsofselectedorganweights(absoluteandrelative)wereconducted wasverticallyadjustablealongtheZ-axisbyslidingupanddownthefourvertical
onallanimals.Fullhistopathologicalexaminationswereconductedonthepre- cornerframepostsofthesystem.TheX-andY-axissensorarraysjointlymoni-
servedorgansandtissuesofallanimalsofthecontrolandhigh-dosegroups. toredhorizontalactivity/movement,theZ-axissensorarraymonitoredverticalactivity/
Histopathologicalexaminationsofkidneys,fromsomeanimalsofthelow-andmiddle- movement,andcomputersoftwarealgorithmstranslatedspatialtemporalbeam
dosegroups,inwhichlesionswereobservedongrossexamination,werealso interruptionpatternsintoanimalactivitypatternsrepresentingtheevaluated
conducted. parameters.
Animalswereexaminedindividually,outsideoftheirhomecageenviron-
2.2.2. Ninety-dayrepeated-doseoraltoxicitystudyinrats ments,intheabsenceofanydisturbingcircumstances.Theevaluatedparameters
Thestudywasconductedinordertoevaluatethepossiblehealthhazards,in- werelocomotionandactivity(timerestinginseconds,timemovinginseconds,time
cludingidentificationoftoxiceffectsandtargetorgans,ofrepeatedoralexposure hyperactiveinseconds,distancetravelledinmeters,locomotorspeedincm/s,and
toZembrin®inmaleandfemaleratsovera90-dayperiodandtodeterminetheNOAEL. overallspeedincm/soccurringinthecentralandperipheralareasandbothareas
OnehundredSPFmaleandfemaleWistarrats,approximately8weeksoldand combined),rearingbehavior(timeinrearinginsecondsandthenumberofrearings
weighing264–316g(males)and171–220g(females)atthestartoftheexperi- inthecenterandperipheralareas;totalrearingandtimeinrearinginsecondsin
mentalperiod,werestratifiedbyweightandrandomlyassignedtofivegroupsof bothareas;andrearingtimeinsecondsincorners1,2,3,and4ofthesystem),and
10rats/sex/groupforadministrationofZembrin®dosesof0(vehicle-control),100, turningbehavior(bothclockwiseandcounterclockwiseinthecentralandperiph-
300,450,and600mg/kgbw/daybygavagefor90-days.Doseselectionwasbased eralareasandbothareascombined).
onthepreviousresultsofthe14-daystudywiththelowestandhighestdosescor- Afteranovernightfast(approximately16hours)followingfinaladministra-
respondingtoapproximately300-and1800-fold,respectively,theproposedhuman tionofthetestarticle,bloodsampleswerecollectedfromtheretroorbitalvenous
uselevelof25mgdaily(357μg/kgina70kgadult).
plexusunderIsofluranCP®anesthesiaafterwhichtheanimalswereeuthanizedby
Theanimalswereobservedtwicedailyformortality.Generalcage-sideobser- exsanguinationfromtheabdominalaorta.Bloodsampleswereanalyzedforhema-
vationsforclinicalsignswereperformedoncedailyafteradministrationofthetest tologicandclinicalchemistryparameters,andgrosspathologicalexaminationsand
article,anddetailedclinicalobservationswereperformed1daypriortothefirst determinationsofselectedorganweights(absoluteandrelative)wereconducted
treatmentandweeklythereafter.Measurementsofbodyweightwereconductedtwice onallanimals.Histopathologicalexaminationswereconductedonthepreserved
duringtheacclimationperiod,onthefirstexperimentaldaypriortotreatment,twice organsandtissuesofallanimalsofthecontrolandhigh-dosegroupsandongross
weeklyduringweeks1–4,onceaweekduringweeks5–13,andimmediatelyprior lesionsobservedinanimalsofthelowerdosegroups.
tosacrifice.Foodintakewasdeterminedandfoodefficiencycalculatedonceweekly.
Ophthalmologicalexaminationwascarriedoutonallanimalspriorto,andoncontrol 2.3. Statisticalanalyses
andhigh-doseanimalsattheendof,theexperimentalperiod.
Afunctionalobservationbatteryperformedduringthefinalweekassessedtests StatisticalanalyseswereconductedusingSPSSPC+software,version4(SPSS,
forgeneralphysicalconditionandbehavior,sensoryreactivitytostimuli,gripstrength, Inc.,Chicago,IL).Bartlett’shomogeneityofvariancetestwasusedtoassessheter-
andlocomotoractivity.Spontaneouslocomotoractivitywasfurtherassessedonone ogeneityofvariancebetweengroups.Aone-wayanalysisofvariance(ANOVA)was
occasionduringthefinalweekusingaLabMasterActiMotlight-beamframessystem. conductedwherenosignificantheterogeneitywasdetectedfollowedbyDuncan’s
TheX,Y,andZaxisinfrared(IR)sensorarraysoftheActiMotlight-beamframes MultipleRangetesttoassessthesignificanceofinter-groupdifferencesifaposi-
systemmonitoredtheactivityoftheanimalsina54×29×41cmcageinsertedinside tiveANOVAresultwasobtained.Kolmogorov–Smirnovtestwasperformedtoexamine

## Page 4

Table3
Summaryofhematologicalfindingsinthe14-dayrepeatedoraltoxicitystudy.
Group(N=5) WBC(109/L) NEU(%) LYM(%) MONO(%) EOS(%) BASO(%) RBC(1012/L) HGB(g/L) HCT(L/L) MCV(fL) MCH(pg) MCHC(g/L) PLT(109/L) RET(%)
(mg/kgbw/day)
Male
Control 8.5±0.7 12.0±1.8 83.9±2.4 2.9±0.9 1.1±0.2 0.1±0.0 8.3±0.2 161.0±8.9 0.4±0.0 53.9±2.2 19.3±0.6 357.8±3.3 980.6±70.8 3.6±0.3
250 8.1±1.1 15.1±4.2 80.0±4.4 3.1±0.8 1.7±0.4 0.1±0.0 8.0±0.4 132.2±50.6 0.4±0.0 54.0±2.0 19.1±0.7 371.4±37.8 823.0±376.9 4.1±0.5
750 8.2±1.4 13.0±1.3 82.1±2.6 3.1±0.6 1.7±1.0 0.1±0.1 7.8±0.7 156.0±8.6 0.4±0.0 56.6±3.7 19.9±1.0 353.0±6.4 959.2±185.9 4.0±0.2
2500 10.7±1.2** 13.6±1.6 81.2±2.0 3.8±0.6 1.3±0.5 0.1±0.0 7.9±0.3 156.8±1.1 0.4±0.0 56.8±1.7 20.0±0.6 351.4±5.3 874.4±35.2* 3.8±0.5
5000 11.1±3.3 19.8±5.0** 75.4±5.5** 3.5±1.6 1.2±0.2 0.1±0.0 8.1±0.2 185.2±7.2 0.4±0.0 55.6±1.6 19.6±0.7 352.2±2.2* 1142.2±159.0 4.3±1.0
Female
Control 7.7±1.1 9.4±2.7 86.2±4.7 3.1±2.0 1.3±0.8 0.1±0.1 8.6±0.4 169.4±4.7 0.5±0.0 54.4±2.1 19.7±0.7 362.6±3.8 948.6±113.6 3.1±0.6
250 7.8±0.8 11.5±2.7 84.8±2.7 2.3±0.6 1.3±0.7 0.1±0.0 8.3±0.2 156.4±3.8** 0.4±0.0** 53.1±2.3 18.9±0.7 356.2±4.7 989.0±99.1 3.7±0.4
750 7.7±1.7 11.3±3.8 84.3±4.4 2.5±0.4 1.9±0.9 0.0±0.1 8.6±0.4 164.0±3.5 0.5±0.0 53.2±2.1 19.1±0.6 359.4±5.5 952.0±69.0 3.0±0.7
2500 6.5±1.0 10.6±1.6 85.6±1.6 2.3±0.9 1.3±0.2 0.2±0.1 8.0±0.2* 155.2±3.6** 0.4±0.0** 54.3±2.7 19.4±0.6 357.2±8.8 1067.0±170.2 4.0±0.7*
5000 6.8±1.2 11.6±2.3 84.3±2.3 2.6±0.8 1.4±0.4 0.1±0.1 8.0±0.4* 156.8±4.7** 0.4±0.0** 55.6±2.3 19.7±0.7 354.4±4.0 1032.6±141.2 3.8±0.4
Abbreviations:WBC,whitebloodcell;NEU,neutrophil;LYM,lymphocyte;MONO,monocyte;EOS,eosinophil;BASO,basophil;RBC,redbloodcell;HBG,hemoglobin;HTC,hematocrit;MCV,meancorpuscularvolume;MCH,
meancorpuscularhemoglobin;MCHC,meancorpuscularhemoglobinconcentration;PLT,platelet;RET,reticulocyte.
Datarepresentthemeanvaluesandthestandarddeviation.
*P<0.05and**P<0.01.
Table4
Summaryofclinicalchemistryinthe14-dayrepeatedoraltoxicitystudy.
Group ALT AST GGT ALP Bilirubin Creatinine Urea Glucose Cholesterol Bileacids Phosphate Calcium Sodium Potassium Chloride Protein Albumin A/G
(N=5) (U/L) (U/L) (U/L) (U/L) (μmol/L) (μmol/L) (mmol/L) (mmol/L) (mmol/L) (μmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (g/L) (g/L) Ratio
(mg/kg
bw/day)
Male
Control 44.7±3.5 112.7±10.6 – 162.6±20.6 1.9±0.2 20.2±2.7 5.1±0.5 6.1±0.8 2.1±0.2 50.8±27.8 2.7±0.2 2.7±0.1 139.2±0.8 4.1±0.2 98.2±1.4 58.5±0.8 32.7±0.7 1.3±0.1
250 43.8±5.3 100.5±11.5 – 187.2±28.1 1.9±0.2 19.7±1.8 5.2±1.1 5.7±0.5 2.2±0.3 45.9±16.2 2.8±0.2 2.8±0.1 139.6±0.5 4.3±0.1 99.8±1.4 57.5±0.6 32.5±0.2 1.3±0.0
750 48.1±3.7 106.2±9.3 – 179.8±30.9 1.9±0.2 20.3±1.9 4.9±0.9 5.8±0.7 2.0±0.2 42.1±14.2 2.9±0.3 2.7±0.1 139.0±0.0 4.1±0.1 98.9±0.5 57.7±2.2 32.1±0.8 1.3±0.1
2500 54.1±5.5* 109.3±8.2 – 181.6±32.8 1.8±0.3 18.4±1.6 5.8±0.7 5.8±0.4 2.4±0.5 42.0±14.9 3.1±0.1* 2.8±0.1 138.8±0.8 4.2±0.1 98.3±0.8 58.4±2.8 32.7±0.8 1.3±0.1
5000 49.4±9.6 91.3±5.4** – 159.6±8.1 1.7±0.3 19.8±2.5 7.6±2.5** 5.7±0.6 2.0±0.1 56.2±42.3 3.4±0.3** 2.8±0.1*,a 137.8±1.1* 4.1±0.2 96.8±2.3 55.2±2.2* 31.2±0.9** 1.3±0.2
Female
Control 42.4±9.6 96.6±10.5 – 103.6±19.2 2.4±0.4 22.4±1.2 5.4±0.6 6.6±0.5 2.2±0.3 27.8±6.6 2.7±0.3 2.7±0.0 141.6±0.5 3.9±0.1 100.1±1.2 58.8±1.8 33.7±1.2 1.3±0.1
250 44.4±10.8 101.6±11.4 – 113.8±23.4 2.0±0.4 23.9±2.6 6.3±0.7 6.3±0.6 2.1±0.2 38.1±29.6 2.5±0.3 2.7±0.1 141.8±1.6 3.9±0.3 99.9±2.6 55.4±1.8 32.1±1.3 1.4±0.1
750 43.6±11.6 103.2±29.1 – 126.6±30.7 2.3±0.6 23.1±2.6 6.7±1.4 5.9±0.2 1.8±0.3 36.6±14.6 2.5±0.2 2.8±0.1 141.2±0.8 4.1±0.3 99.9±0.9 57.9±2.0 33.5±0.9 1.4±0.1
2500 48.8±6.7 99.1±11.5 – 110.8±18.5 1.9±0.2* 22.0±1.6 5.8±0.6 6.3±0.7 1.8±0.4 55.0±37.5 2.5±0.1 2.7±0.1 141.8±1.1 4.1±.02 100.2±1.7 57.6±1.4 33.0±1.0 1.3±0.1
5000 45.2±15.3 91.1±9.9 – 125.6±22.8 1.7±0.1** 21.0±2.0 6.7±1.8 5.9±0.7 2.1±0.2 56.8±37.5 2.6±0.1 2.7±0.1 141.4±2.1 3.9±0.3 99.1±3.3 55.4±2.9* 31.7±1.4* 1.3±0.1
Abbreviations:ALT,alaninetransaminase;AST,aspartatetransaminase;GGT,gamma-glutamyltransferase;ALP,alkalinephosphatase;A/G,albumintoglobulinratio;–,belowquantitationlimit(7U/L).
Datarepresentthemeanvaluesandthestandarddeviation.
*P<0.05and**P<0.01.
aApparenceofsimilaritytonon-significantresultsduetorounding.
T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199
193

## Page 5

Table5
Summaryofnecropsyfindingsinthe14-dayrepeatedoraltoxicitystudy.
Organs Dosegroup(mg/kgbw/day) Control 250 750 2500 5000
Observations
Male
Nomacroscopicfindings 5/5 5/5 4/5 3/5 4/5
Kidneys: Pyelectasia 0/5 0/5 1/5 1/5 0/5
Pale 0/5 0/5 0/5 1/5 0/5
Prostate: Smallerthannormal 0/5 0/5 0/5 0/5 1/5
Female
Nomacroscopicfindings 4/5 2/5 5/5 3/5 3/5
Kidneys: Pyelectasia 0/5 0/5 0/5 1/5 0/5
Uterus: Hydrometria 1/5 3/5 0/5 2/5 2/5
Datarepresentthenumberofanimalswithobservation/numberofanimals observed.
thedistributionofdatawheresignificantheterogeneitywasdetectedbyBartlett’s
test,andKruskal–Wallisnon-parametricone-wayANOVA,followedbytheMann–
WhitneyU-testforinter-groupcomparisonsofpositiveresults,wasusedinthecase
ofanon-normaldistribution.AP-valueof<0.05wasconsideredstatistically
significant.
3. Results
3.1. Fourteen-dayrepeatedoraltoxicitystudyinrats
Nomortalitywasobservedinanyofthedosegroupsduringthe
14-daytreatmentperiod.Theanimalsexhibitednormalbehavior
andphysicalconditionwithnosignificantabnormalitiesinclini-
cal signs observed throughout the study. Slight to moderate or
moderatetransientsalivationwasobservedimmediatelyafterad-
ministrationofthetestarticleinallhigh-dosegroupfemaleanimals,
occurringwithfrequenciesfromfivetonineobservationsperanimal
betweendays6and14,infouroffivehigh-dosegroupmales,oc-
curringwithfrequenciesfromfivetonineobservationsperanimal
betweendays5and13,andinonemaleinthe2500mg/kgdose
groupondays8and13.Thesefindingswereregardedasinciden-
talandwithouttoxicologicalsignificancebecausetheywereoflow
degree,transientinoccurrence,andofshortduration(ceasingwithin
afewminutesafteradministrationofthetestarticle)andtherewere
nootherrelatedfindings.Thispresentation,occurringinonlythe
twohighestdosegroups,isconsistentwithanetiologyduetoaphys-
icalorchemicalfeatureofthetestarticle,suchastaste,although suchpropertiesofthetestarticlewerenotassessed.Transientsal-
ivationisalsohistoricallyobservedinvehicle-treatedanimals.No
test article-related effects on body weight or food consumption
(Table2)wereobservedduringthestudy,andthemeanweight,
weightgain,foodconsumption,andfoodefficiencyweresimilar
betweenthecontrolandtreatmentgroupsthroughoutthestudy.
Noeyelesionswereobservedonophthalmologicexaminationin
anyanimalsbeforeorafterthetreatmentperiod.
Noremarkablealterationswereobservedinhematologicorclin-
icalchemistryparameters.Asmallnumberofstatisticallysignificant
differencesbetweentreatedandcontrolanimals,observedamong
sexes (Tables3 and 4), were not considered to be test article-
relatedortoxicologicallymeaningfulbecauseof lowmagnitude,
singleoccurrence,nodosedependency,absenceofrelatedgrossor
histopathologicalfindings,andbecauseallobservationsremained
withinhistoricalcontrolrangesofthelaboratory.
Ongrosspathologicalexamination,pyelectasiawasobservedin
onemaleofthe750mg/kgdosegroupandonemaleandonefemale
ofthe2500mg/kgdosegroup.Renalpalenesswasobservedinone
maleofthe2500mg/kgdosegroup.Asmallerthannormalpros-
tatewasobservedinonemale(animal#2412)of thehigh-dose
group,andslightormoderatehydrometra(indicativeoftheestrous
cycleofthefemaleanimals)wasobservedinonetothreefemales
6elbaT
.ydutsyticixotlarodetaeperyad-41ehtnithgiewnagrofoyrammuS
)%(thgiewydobotevitalerthgiewnagrO
)yad/wbgk/gm()5=N(puorG
slanerdA
sedimydidipE
setseT
neelpS
sumyhT
traeH
syendiK
reviL
niarB
elaM
300.0±220.0
660.0±562.0
031.0±480.1
910.0±952.0
030.0±561.0
720.0±463.0
350.0±197.0
790.0±520.3
230.0±056.0
lortnoC
300.0±220.0
420.0±132.0
480.0±480.1
060.0±562.0
020.0±551.0
020.0±433.0
830.0±167.0
601.0±648.2
730.0±536.0
052
200.0±120.0
540.0±652.0
990.0±010.1
840.0±182.0
230.0±351.0
420.0±143.0
640.0±287.0
461.0±820.3
330.0±026.0
057
400.0±420.0
650.0±632.0
021.0±190.1
520.0±972.0
310.0±741.0
240.0±243.0
280.0±028.0
361.0±840.3
640.0±536.0
0052
500.0±420.0
850.0±762.0
701.0±630.1
640.0±582.0
510.0±851.0
140.0±053.0
060.0±248.0
*072.0±803.3
360.0±546.0
0005
)%(thgiewniarbotevitalerthgiewnagrO
)yad/wbgk/gm()5=N(puorG
slanerdA
seiravO
suretU
neelpS
sumyhT
traeH
syendiK
reviL
thgiewydoB
elameF
07.0±11.5
17.1±30.8
33.11±14.23
12.6±48.23
39.3±38.51
72.9±00.64
18.4±79.68
04.92±32.153
52.4221±8.42611
lortnoC
15.0±12.5
85.1±53.01
82.41±44.93
70.31±99.14
*53.6±90.52
36.01±81.15
78.11±37.79
04.501±33.014
68.4691±5.77231
052
06.0±60.5
91.2±00.9
13.3±40.52
56.7±19.43
13.4±60.91
70.9±25.54
57.7±20.29
08.91±21.353
63.2501±3.52611
057
30.1±28.4
18.1±83.8
21.9±47.63
48.01±46.83
87.6±48.91
93.8±51.54
72.41±34.49
19.28±55.493
20.0561±2.90521
0052
47.0±45.4
82.2±06.7
27.8±80.33
49.2±85.53
81.2±77.71
77.5±73.24
34.7±17.89
56.32±60.963
76.876±8.85911
0005
.noitaiveddradnatsehtdnaseulavnaemehttneserperataD
.50.0<P*
194 T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199

## Page 6

T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199 195
Table7
Summaryofhistopathologyfindingsinthe14-dayrepeatedoraltoxicitystudy.
Organs Dosegroup(mg/kgbw/day) Control 250 750 2500 5000
Observations
Male
Nomicroscopicfindings 5/5 / / / 4/5
Kidneys: Nomicroscopicfindings 5/5 / 1/1 2/2 5/5
Subacutelymphocyticpyelitis 0/5 / 0/1 0/2 1/5
Urinarybladder: Subacutelymphocyticcystitis 0/5 / / / 1/5
Prostate: Subacutelymphocyticprostatitis 0/5 / / / 1/5
Female
Nomicroscopicfindings 3/5 / / / 5/5
Kidneys: Nomicroscopicfindings 5/5 / / 1/1 5/5
Uterus: Dilatation 2/5 / / / 0/5
Abbreviations:/,notexamined.
Datarepresentthenumberofanimalswithobservation/numberofanimalsobserved.
pergroupinthecontrolgroupandall,exceptthe750mg/kg,dose grosspathologicallesionswereobservedinanyanimalsofthetreat-
groups(Table5).Thesmallprostate,whichisseenoccasionallyin mentorcontrolgroups.
untreatedexperimentalrats,wasconsideredtobeanindividualal- Absoluteandrelativeorganweightsweresimilaramonganimals
terationunrelatedtoadministrationof thetest-article.Therenal inthetreatmentandcontrolgroups,withtheexceptionofaslight
changes(pyelectasiaandpaleness)andhydrometraarespecies- butstatisticallysignificant(P<0.05)differenceintheweightofthe
specificalterationsthatoccurinuntreatedanimalsofthisspecies liverrelativetobodyweightinmalesofthehigh-dosegroupand
andstrainandwerenotconsideredtobetestarticle-related.Noother a slight but significant (P<0.05) increase in thymus weight
Table8
Summaryofmeanbodyweightandmeanfoodintakedatainthe90-dayrepeatedoraltoxicitystudy.
Meanbodyweight(g) Initial(Day0) Midway(Day42) End(Day89)
Male
Control(N=10) 295.2±13.57 446.9±34.04 505.3±36.02
100mg/kgbw/day(N=10) 293.4±15.22 429.4±55.08 479.0±79.16
300mg/kgbw/day(N=10) 292.9±11.35 437.7±34.62 497.5±38.81
450mg/kgbw/day(N=10) 290.5±11.54 424.8±35.55 481.3±51.75
600mg/kgbw/day(N=10) 291.1±11.25 450.1±38.58 510.0±59.13
Female
Control(N=10) 194.3±11.91 255.4±25.95 274.6±29.79
100mg/kgbw/day(N=10) 193.0±13.86 254.5±21.27 268.7±24.52
300mg/kgbw/day(N=10) 191.5±8.68 260.1±17.79 276.3±23.22
450mg/kgbw/day(N=10) 191.8±9.22 259.5±22.09 277.6±26.05
600mg/kgbw/day(N=10) 193.2±11.16 261.6±22.17 277.5±28.00
Meanfoodconsumption(g/rat/day) Week1(Days0–7) Week6(Days35–42) Week13(Days84–89)
Male
Control(N=10) 31.2±2.51 30.1±3.20 26.1±2.07
100mg/kgbw/day(N=10)(%Deviationfromcontrol) 28.7±2.65(−8)* 28.2±3.89(−6) 23.6±8.33(−10)
300mg/kgbw/day(N=10)(%Deviationfromcontrol) 28.2±3.21(−9)* 29.8±3.35(−1) 28.1±2.38(8)
450mg/kgbw/day(N=10)(%Deviationfromcontrol) 27.4±3.12(−12)** 28.2±2.65(−6) 25.9±3.18(−1)
600mg/kgbw/day(N=10)(%Deviationfromcontrol) 27.4±1.75(−12)** 29.6±3.16(−2) 26.0±2.58(0)
Female
Control(N=10) 20.9±2.15 20.5±1.92 18.3±3.08
100mg/kgbw/day(N=10)(%Deviationfromcontrol) 19.8±2.01(−6) 20.2±1.85(−1) 17.8±2.03(−3)
300mg/kgbw/day(N=10)(%Deviationfromcontrol) 19.8±1.55(−5) 21.7±1.56(6) 19.0±2.19(4)
450mg/kgbw/day(N=10)(%Deviationfromcontrol) 19.5±2.23(−7) 21.2±2.13(3) 19.0±2.42(4)
600mg/kgbw/day(N=10)(%Deviationfromcontrol) 18.7±1.59(−11) 20.2±1.95(−1) 16.8±1.79(−8)
Meanbodyweightdatarepresentthemeanandthestandarddeviationatthebeginning,mid-waythroughandendofthestudy.
Foodintakedatarepresentthemeanvalueperratperdayandpercentdeviationfromcontrolatthebeginning,mid-waythrough,andendofthestudy.
*P<0.05and**P<0.01.
Table9
Summaryofselectedfinalhematologicalfindingsinfemaleanimalsinthe90-dayrepeatedoraltoxicitystudy.
Dose(mg/kgbw/day) WBC(109/L) NEU(%) LYM(%) MONO(%) EOS(%) BASO(%)
Control(N=10) 6.21±1.54 11.91±4.13 83.68±4.27 2.36±0.81 2.04±0.95 0.01±0.03
100(N=10) 6.22±1.73 19.52±10.49* 75.04±10.85 2.92±0.81 2.47±0.54 0.05±0.08
300(N=10) 5.54±2.14 16.70±5.33 78.31±6.36 2.96±1.76 2.02±0.82 0.01±0.03
450(N=10) 5.45±1.57 16.27±5.95 79.08±7.85 2.37±1.31 2.21±1.13 0.07±0.12
600(N=10) 5.21±1.56 19.75±6.50* 75.99±7.38 2.32±0.95 1.94±0.61 0.00±0.00
Abbreviations:Hb,hemoglobin;HTC,hematocrit;RBC,redbloodcell;WBC,whitebloodcell;NEU,neutrophil;LYM,lymphocyte;MONO,monocyte;EOS,eosinophil;BASO,
basophil.
Datarepresentthemeanvaluesandthestandarddeviation.
* P<0.05.

## Page 7

Table10
Summaryofclinicalchemistryinthe90-dayrepeatedoraltoxicitystudy.
Group(N=10) ALT(U/L) AST(U/L) GGT(U/L) ALP(U/L) Bilirubin Creatinine Urea Glucose Cholesterol
(mg/kgbw/day) (μmol/L) (μmol/L) (mmol/L) (mmol/L) (mmol/L)
Male
Control 62.65±16.61 105.62±15.45 0.68±0.39 80.30±11.59 2.85±0.36 26.44±3.95 6.64±0.78 6.42±0.32 2.30±0.51
100 60.89±15.55 113.32±24.79 0.84±0.65 118.90±91.51 2.74±0.82 26.58±4.04 7.86±0.95** 6.30±0.94 2.19±0.27
300 67.91±14.53 115.60±21.61 0.81±0.56 91.10±17.80 2.69±0.50 24.91±2.93 7.44±0.91 7.21±0.59** 2.48±0.80
450 62.13±11.66 108.86±11.28 0.55±0.28 78.30±18.64 2.70±0.60 27.13±2.81 7.39±0.69 7.60±0.88** 2.46±0.44
600 52.68±11.77 101.03±11.44 0.89±0.39 75.40±14.55 2.75±0.33 27.20±3.81 6.56±0.90 6.39±0.68 2.32±0.43
Female
Control 55.52±16.48 121.21±34.44 0.46±0.30 53.50±12.91 2.68±0.45 29.98±4.90 7.15±1.52 5.61±0.71 2.23±0.44
100 55.32±19.10 116.73±42.26 1.54±0.94** 53.00±7.13 2.73±0.63 28.65±3.84 7.18±0.97 5.62±1.04 2.23±0.61
300 72.34±41.08 126.42±40.12 0.98±0.39** 86.70±23.29** 2.78±0.50 28.26±2.98 7.33±1.03 6.29±1.21 2.10±0.35
450 77.06±68.05 118.06±45.05 1.00±0.96 83.80±24.39** 2.78±0.32 26.56±3.37 6.82±1.11 6.15±1.11 2.37±0.39
600 105.35±159.83 156.48±174.89 1.44±1.51** 51.50±10.96 2.77±0.81 30.77±2.35 6.30±1.09 5.63±1.29 2.00±0.33
Group(N=10) Bileacids Phosphate Calcium Sodium Potassium Chloride Protein(g/L) Albumin A/GRatio
(mg/kgbw/day) (μmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (g/L)
Male
Control 65.14±26.73 2.05±0.13 2.60±0.14 140.70±2.41 4.33±0.22 102.95±1.83 59.66±3.53 31.86±1.66 1.17±0.13
100 60.31±24.76 2.15±0.29 2.61±0.25 140.80±2.49 4.41±0.41 102.80±2.55 60.37±3.30 31.85±2.33 1.12±0.11
300 59.10±14.18 2.15±0.29 2.75±0.07* 141.10±1.37 4.28±0.25 103.15±1.46 62.41±2.24 33.53±0.74** 1.17±0.09
450 56.57±23.33 2.36±0.26 2.82±0.17** 139.10±2.13 4.36±0.12 102.09±1.26 63.87±5.28* 32.64±1.49 1.07±0.19
600 40.81±19.81 2.16±0.28 2.73±0.09 141.40±1.07 4.27±0.25 103.52±0.97 64.01±2.63* 33.50±0.97* 1.12±0.09
Female
Control 56.25±50.29 1.70±0.23 2.65±0.14 141.10±1.85 3.87±0.21 105.20±2.07 60.12±5.70 33.11±2.72 1.24±0.12
100 78.81±49.51 1.60±0.22 2.61±0.08 141.50±1.65 3.88±0.30 104.47±2.18 61.98±3.21 34.16±1.66 1.25±0.18
300 45.02±26.15 1.74±0.25 2.70±0.12 142.30±1.83 3.89±0.27 105.53±1.57 63.60±3.16 34.83±1.50 1.22±0.06
450 45.85±14.34 1.88±0.40 2.62±0.18 142.40±1.71 3.94±0.24 105.93±1.68 64.10±4.08 34.69±1.75 1.19±0.16
600 62.97±63.69 1.63±0.33 2.66±0.07 141.60±0.70 3.81±0.23 105.53±1.37 62.07±3.77 34.57±1.66 1.26±0.10
Abbreviations:ALT,alaninetransaminase;AST,aspartatetransaminase;GGT,gamma-glutamyltransferase;ALP,alkalinephosphatase;A/G,albumintoglobulinratio.
Datarepresentthemeanvaluesandthestandarddeviation.
*P<0.05and**P<0.01.
196
T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199

## Page 8

T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199 197
Table11
Summaryofnecropsyfindingsinthe90-dayrepeatedoraltoxicitystudy.
Organs Dosegroup(mg/kgbw/day) Control 100 300 450 600
Observations
Male
Nomacroscopicfindings 9/10 9/10 9/10 9/10 10/10
Testes: Smallerthannormal–bilateral 1/10 0/10 0/10 0/10 0/10
Thoraciccavity: Bloodfilledformation 0/10 1/10 0/10 0/10 0/10
Kidneys: Pyelectasia–unilateral 0/10 0/10 1/10 0/10 0/10
Cervicallymphnodes: Hemorrhagicinfiltration 0/10 0/10 0/10 1/10 0/10
Female
Nomacroscopicfindings 6/10 10/10 6/10 7/10 8/10
Uterus: Hydrometria 4/10 0/10 4/10 3/10 2/10
Datarepresentthenumberofanimalswithobservation/numberofanimalsobserved.
relativetobrainweightinfemalesofthelow-dosegroup(Table6). systemmeasuredparametersofspontaneouslocomotoractivity(lo-
Duetothelackofadose-relatedeffect,thesmallmagnitudeofthe comotion,activity,spatialparameters,turningbehavior,andrearing
differences,andthelackofgrossorhistopathologicallesions,these behavior)betweenthetestarticledosegroupsandcontrolgroups.
changeswereconsideredtobewithouttoxicologicalrelevanceand Notestarticle-relatedeffectsonbodyweightorfoodconsump-
unrelatedtotestarticleadministration. tionwereobservedduringthestudy(seeTable8).Afewstatistically
Histopathologicalexamination(Table7)revealedthepresence significant transient fluctuations in mean body weight gain ob-
ofmoderatesubacutelymphocyticpyelitis,cystitis,andprostati- servedamongthesexesanddosegroupswereoflowdegreeand
tisinasinglemaleanimal(#2412)ofthehigh-dosegroup.These notdose-dependent.Meanfoodconsumptionwasslightly,butsta-
observationswereconsideredindicativeoflymphocyticinflamma- tisticallysignificantly,lowerinalltreatedmaledosegroupscompared
tionandwererelatedtoobservationsinthissameanimalofslightly tocontrolsduringthefirstweekofthestudy.Thedifferencewas
(marginaltothehistoricalrange)increasedneutrophilpercentage transientandoflowmagnitude,unrelatedtobodyweightorweight
(27.7vs.27.1%)andurea(11.93vs.11.75mmol/L)comparedtohis- gain,andremainedwithinthehistoricalrangesofthelaboratory.
toricalcontrolranges.Thecollectivefindingsinanimal#2412were Thereforethefindingwasnotconsideredtobeoftoxicologicalrel-
consideredtobeofnotoxicologicalsignificanceandunrelatedto evance. No eye lesions were observed on ophthalmologic
testarticleadministrationduetotheiroccurrenceasanindividu- examinationinanyanimalsbeforeorafterthetreatmentperiod.
aldisorder.Thisconclusionwassupported,retrospectively,bythe Statisticallysignificantelevationsinwhitebloodcellcount,re-
absenceofsimilarfindingsinanyanimalsofthe90-daystudy,herein ticulocyte count, and percentage of neutrophils together with a
alsoreported.Dilatationofuterinehorns,indicatingestrusphase statisticallysignificantdecreaseinpercentageoflymphocyteswere
ofthesexualcycleandwithoutassociatedpathologicallesions,was observedinasinglemale(animal#15)ofthe100mg/kgbw/day
observedintwooffivefemalesofthecontrolgroup.Nootherhis- group (isolated clinical observations (reported above) and iso-
topathologicallesionswereobservedinanyorgansortissuesofany latedgrosspathologicalfindingswereobservedinthesameanimal)
animalsinthecontrolorhigh-dosegroups.Nohistopathological andwereconsideredindicativeofanindividuallesionunrelatedto
findingswereobservedinthekidneysofasmallnumberofanimals thetestarticle.Nootherremarkablealterationswereobservedin
inthemiddledosegroupswherethereweregrossobservationsof hematologicorclinicalchemistryparameters;however,slightbut
species-specificalterations. statisticallysignificantdifferencesinneutrophilpercent(between
Nosignsoftoxicitythatwereconsideredrelatedtoadministra- femalesofthe100and600mg/kgbw/daygroupsandcontrols)and
tion of Zembrin® by gavage were observed in male or female variousclinicalchemistryparameters(betweenmaleandfemale
Crl:(WI)BRWistarratsatdosesof250,750,2500,or5000mg/kg animalsofalldosegroupsandcontrols)wereobserved(Tables9
bw/dayfor14consecutivedays.TheNOAELwasdeterminedtobe and10),butwerenotconsideredtobetestarticle-relatedortox-
5000mg/kgbw/day. icologicallymeaningfulbecauseof lowmagnitude,lackof dose-
relationship,andabsenceofrelatedpathologicalfindingsandbecause
3.2. Ninety-dayrepeated-doseoraltoxicitystudyinrats allobservationsremainedwithinormarginaltohistoricalcontrol
rangesofthelaboratory.
Nomortalitywasobservedatanyofthetesteddoselevelsduring Ongrossexamination,abloodfilledthoracicformationwasob-
the90-daytreatmentperiod.Theanimalsexhibitednormalbehav- servedinonemale(animal#15)ofthelow-dosegroup.Together
iorandphysicalconditionwithnosignificantabnormalitiesinclinical withthewhitebloodcellabnormalitiesandclinicalobservations
signsobservedthroughoutthestudywithoneexception.During observedinthisanimal,thefindingisconsistentwithgavageirri-
thefinal2weeksofthestudy,onemale(animal#15)ofthelow tationand,therefore,wasnotconsideredtoxicologicallyrelevant.
dosegroupexhibitedslightlydecreasedactivityandslightdyspnea Severalothersporadiclesionswereobservedinmaleanimalsofthe
ondays74–77;moderatelydecreasedactivity,moderatedyspnea, controlgroupandallbutthehigh-dosegroupofthetreatedanimals
andmoderatepiloerectionondays87–89;andslightlysanguine- ongrosspathologicalexamination(Table11).Theselesionswere
ousnasalorificesondays87and88.Becausetheseobservations isolated to individual animals, were not dose related, and are
were limited to only one animal in the low dose group, the ob- commonfindingsinuntreatedratsandwere,therefore,notcon-
servedsignswerenotconsideredtobeoftoxicologicalconcern. sidered to be of toxicological concern or test article-related.
Nodifferencesinbehavior,sensoryreactionstovarioustypesof Hydrometra,relatedtothesexualcycleandofnotoxicologicalrel-
stimuli,gripstrength,orlocomotoractivitybetweentreatedanimals evance,wasobservedinsomefemalesofthecontrolgroupandall
andcontrolswereobservedduringthefunctionalobservationbattery. butthelowdosegroupoftreatedanimals(Table11).
Observationsofreducedrightingreflexoccurredwithsimilarin- Thelivertobodyweightratioofhighdosemaleswasslightly
cidenceinanimalsofalldosegroupswhencomparedtothecontrol lesscomparedtocontrolmales,andstatisticallysignificantdiffer-
groups(greatestincidencesoccurredinthecontrolgroups).There encesinmeanadrenalweightandadrenaltobodyweightratioand
were no significant differences in the ActiMot light-beam frame meanhearttobodyweightratiowereobservedinhigh-dosefemales

## Page 9

(Table12).Thesedifferenceswerenotconsideredtohavebiologi-
calsignificance,andnootherdifferencesinabsoluteorrelativeorgan
weightswereobservedbetweencontrolandtreatedanimals.
Sporadiclesionsuponhistopathologicalexamination(Table13)
were revealed with similar frequency in the control and high-
dosegroupandwerenotconsideredtreatment-related.Observed
lesionswerealveolaremphysema,consideredaconsequenceofex-
sanguination;hyperplasiaofbronchusassociatedlymphoidtissue,
aphysiologicalphenomenon;alveolarhistiocytosis,acommonin-
cidentalfindinginolderrats;anddilatationoftheuterinehorns,
indicating estrus phase of the sexual cycle. Sporadic lesions ob-
servedinasinglekidneyofa300mg/kgdosegroupmale,acervical
lymphnodeofa450mg/kgdosegroupmale,andthetestesofa
controlgroupmalewereconsideredunrelatedtothetestarticledue
tothelowfrequencyoftheiroccurrenceasisolatedindividualdis-
ordersinanimalsofthecontrolandlowerdosegroupsonlyand
theircommonobservationinuntreatedexperimentalratsofthis
strain with similar age. No other microscopic lesions were ob-
servedinanyorgansortissuesofcontrolortreatedanimalssubjected
tohistopathologicalexamination.
Nosignsoftoxicitythatwereconsideredrelatedtoadministra-
tion of Zembrin® by gavage were observed in male or female
Crl:(WI)BRWistarratsatdoses100,300,450,and600mg/kgbw/
day for 90 consecutive days. The NOAEL was determined to be
600mg/kgbw/day.
4. Discussionandconclusion
The present studies are the first formal in vivo toxicological
studiesofanextractofS.tortuosum(Zembrin®)andprovidesup-
portingevidenceforthesafetyandtolerabilityfindingsinthefirst
clinical study (Nell et al., 2013). The repeated administration of
Zembrin®for90daysbygavagetoWistarratsresultedinaNOAEL
of600mg/kgbw/day.Applyinga100-folduncertaintyfactortocom-
pensate for inter- and intraspecies differences, results can be
extrapolated to an acceptable daily intake of 420mg by a 70kg
human.Zembrin®isintendedtobeusedasaningredientinfunc-
tionalfoods,beverages,anddietarysupplements.Therecommended
consumptionis25mgperday.Thisis0.357mg/kgbw/dayina70kg
adult,whichis1680timeslessthantheNOAELof600mg/kgbw/
day.Theindigenousclassificationasamak,ormildvariety,ofthe
S.tortuosum variety selected for extraction of Zembrin® is sup-
portedbyourfindingsthattherewerenochangesincentralnervous
systemsigns,behavior,activity,weight,orfoodintakeatanyofthe
dosesstudied.
In previous safety assessments (Harvey, 2008, unpublished;
Jurkowski, 2008, unpublished), we observed that ≤100μg/mL of
Zembrin®hadnoeffectonseveralmammaliancelllinesanddidnot
causegenotoxicityinvitro,asrevealedbyassaysforinductionof
micronucleiinCHO-K1andV79cells,orbacterialreversioninan
Ames test. At 10μg/mL Zembrin® did partly reduce K+ currents
throughhERGchannelsinwholecellpatchclampexperimentsal-
thoughthisconcentrationisunlikelytobeachievedinvivo.
Asmallseriesofclinicalcasestudiesofsubjectswhoingested
dailyamountsof50–100mgofuncharacterizedmilledS.tortuosum
rawmaterialreportedpositivefindingsonmoodandfeelingsof
anxiety(Gericke,2001),andaninvivostudyofanuncharacterized
extractofS.tortuosuminratsdemonstratedapositiveoutcomeon
thebehavioraleffectsofrestraintstress(Smith,2011).Positiveeffects
onwell-being,includingimprovedstresscopingandimprovedsleep,
werenotedinpatientdiariesbysomeparticipantstakingextract
S.tortuosum(Zembrin®)inthefirstclinicalstudyofthisextract(Nell
etal.,2013).Arecentdouble-blindplacebo-controlledcross-over
pharmaco-fMRI study of a single 25mg dose administration of
Zembrin®inhealthyuniversitystudentsdemonstratedsignificant
attenuation of amygdala reactivity to fearful faces under low
21elbaT
.ydutsyticixotlarodetaeperyad-09ehtni)%(thgiewydobotevitalerthgiewnagrO
dioryhtarap+dioryhT
slanerdA
/sedimydidipE
suretU/setseT
neelpS
sumyhT
traeH
syendiK
reviL
niarB
)01=N(puorG
seiravO
)yad/wbgk/gm(
sedimydidipE
setseT
elaM
6200.0±0700.0
9100.0±1510.0
360.0±733.0
071.0±667.0
130.0±691.0
110.0±160.0
620.0±192.0
660.0±026.0
012.0±345.2
830.0±444.0
lortnoC
1200.0±0700.0
9200.0±9410.0
540.0±073.0
511.0±948.0
230.0±302.0
910.0±560.0
920.0±392.0
940.0±506.0
881.0±394.2
660.0±264.0
001
4100.0±7600.0
5200.0±5410.0
050.0±263.0
460.0±118.0
710.0±981.0
310.0±650.0
140.0±992.0
660.0±046.0
932.0±785.2
230.0±534.0
003
2100.0±6500.0
8100.0±6310.0
630.0±363.0
460.0±408.0
420.0±402.0
310.0±260.0
320.0±982.0
830.0±726.0
981.0±315.2
630.0±834.0
054
9100.0±8600.0
5200.0±3410.0
540.0±633.0
751.0±318.0
310.0±291.0
210.0±960.0
810.0±172.0
560.0±895.0
*531.0±933.2
740.0±514.0
006
seiravO
suretU
elameF
700.0±310.0
600.0±730.0
310.0±160.0
180.0±772.0
130.0±232.0
020.0±790.0
320.0±953.0
150.0±456.0
251.0±435.2
760.0±327.0
lortnoC
200.0±900.0
400.0±530.0
010.0±550.0
530.0±842.0
840.0±832.0
210.0±390.0
920.0±743.0
340.0±076.0
791.0±075.2
670.0±257.0
001
300.0±800.0
600.0±230.0
210.0±350.0
760.0±842.0
320.0±332.0
420.0±980.0
140.0±073.0
060.0±346.0
821.0±985.2
360.0±817.0
003
200.0±800.0
400.0±330.0
900.0±850.0
250.0±152.0
620.0±632.0
710.0±870.0
810.0±233.0
140.0±156.0
452.0±206.2
970.0±707.0
054
8200.0±9700.0
**1300.0±0030.0
900.0±450.0
560.0±242.0
820.0±322.0
510.0±680.0
*920.0±623.0
040.0±336.0
751.0±025.2
380.0±807.0
006
.noitaiveddradnatsehtdnaseulavnaemehttneserperataD
.10.0<P**dna50.0<P*
198 T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199

## Page 10

T.S.Murbachetal./FoodandChemicalToxicology74(2014)190–199 199
Table13
Summaryofhistopathologyfindingsinthe90-dayrepeatedoraltoxicitystudy.
Organs Dosegroup(mg/kgbw/day) Control 100 300 450 600
Observations
Male
Cervicallymphnodes: Hemorrhages 0/10 / / 1/1 0/10
Epididymides: Lackofmaturespermatozoa 1/10 / / / 0/10
Kidneys: Pyelectasia–unilateral 0/10 / 1/1 / 0/10
Lungs: Alveolaremphysema 2/10 / / / 2/10
Alveolarhistiocytosis 1/10 / / / 1/10
HyperplasiaofBALT 2/10 / / / 2/10
Testes: Decreasedintensityofspermatogenesis 1/10 / / / 0/10
Female
Lungs: Alveolaremphysema 1/10 / / / 2/10
Alveolarhistiocytosis 1/10 / / / 1/10
HyperplasiaofBALT 1/10 / / / 2/10
Uterus: Dilatation 4/10 / / / 2/10
Abbreviations:/,notexamined;BALT,bronchusassociatedlymphoidtissue.
Datarepresentthenumberofanimalswithobservation/numberofanimalsobserved.
Organswithoutlesionsin10/10controlorhigh-doseanimalsarenotshown.
perceptualloadconditionsandreducedamygdala–hypothalamus References
coupling(Terburgetal.,2013).
The above clinical and preclinical results support the sug- FDA,2003a.Redbook2000.Toxicologicalprinciplesforthesafetyassessmentoffood
gestedpotentialofZembrin®asbeneficialtopromotionofasense ingredients.IV.C.3.a.Short-termtoxicitystudieswithrodents.
FDA,2003b.Redbook2000.Toxicologicalprinciplesforthesafetyassessmentoffood
ofemotionalwell-being,calmingeffect,andstressrelief.Thepresent
ingredients.IV.C.4.a.Subchronictoxicitystudieswithrodents.
invivotoxicologicalstudiesonZembrin®,togetherwiththeclini- Gericke,N.,2001.ClinicalapplicationofselectedSouthAfricanmedicinalplants.Aust.
calevidenceof safetyandtolerability(Nelletal.,2013)andour J.Med.Herbalism.13(1),3–18.
Gericke,N.,Viljoen,A.M.,2008.Sceletium—areviewupdate.J.Ethnopharmacol.119
unpublishedinvitrosafetystudies,provideafoundationforfuture
(3),653–663.
studiesdesignedtoevaluatehealth-promotingapplicationsofextract Hirabayashi,M.,Ichikawa,K.,Fukushima,R.,Uchino,T.,Shimada,K.,2002.Clinical
S.tortuosum(Zembrin®)infunctionalfoods,beverages,anddietary applicationofSouthAfricanteaondementiadog(Englishtranslationfrom
supplements. Japanese).Jpn.J.SmallAnim.Pract.21(2),1–6.
Hirabayashi,M.,Ichikawa,K.,Yoshii,A.,Uchino,T.,Shimada,K.,2004.Clinicaleffects
ofSouthAfricanteaforcat(EnglishtranslationfromJapanese).Jpn.J.SmallAnim.
Funding Pract.23(2),1–6.
Nell,H.,Siebert,M.,Chellan,P.,Gericke,N.,2013.Arandomized,double-blind,
parallel-group,placebo-controlledtrialofextractSceletiumtortuosum(Zembrin)
Theauthor(s)disclosethatfinancialsupportfortheresearchde- inhealthyadults.J.Altern.Complement.Med.19,898–904.
scribedhereinwasprovidedbyH.L.HallandSons,Ltd,SouthAfrica. NRC,2011.GuidefortheCareandUseofLaboratoryAnimals.Committeeforthe
UpdateoftheGuidefortheCareandUseofLaboratoryAnimals,Institutefor
LaboratoryAnimalResearch,DivisiononEarthandLifeStudies,NationalResearch
Conflictofinterest Council,WashingtonDC.
OECD,1998.OECD408.Guidelineforthetestingofchemicals:repeateddose90-day
oraltoxicitystudyinrodents.(Section4,No.408,adopted21September):1–10.
DrNigelGerickeistheDirector,MedicalandScientificAffairs, OECD,2008.OECDGuidelinesforthetestingofchemicals,No.407.Repeateddose
ofHG&HPharmaceuticals(Pty)Ltd,thecompanythathasdevel- 28-dayoraltoxicitystudyinrodents.(Adopted3October2008):1–13.
Pappe,L.1868.MesembryanthemumtortuosumLin.In:FloraeCapensisMedicae
opedtheextractofSceletiumtortuosum(Zembrin®).Theremaining
Prodromus;or,AnEnumerationofSouthAfricanPlantsUsedAsRemediesBy
author(s) declared no conflicts of interest in regard to the re- TheColonistsOfTheCapeOfGoodHope.ThirdEdition,Paragraph39,page17.
search,authorship,and/orpublicationofthisarticle. W.Brittain,BureauStreet,CapeTown.
Shikanga,E.,Viljoen,A.,Combrinck,S.,Marston,A.,Gericke,N.,2012.Thechemotypic
variationofSceletiumtortuosumalkaloidsandcommercialproductformulations.
Transparencydocument Biochem.Syst.Ecol.44,364–373.
Shikanga,E.A.,Hamman,J.H.,Chen,W.,Combrinck,S.,Gericke,N.,Viljoen,A.M.,2012.
InvitropermeationofmesembrinealkaloidsfromSceletiumtortuosumacross
TheTransparencydocumentassociatedwiththisarticlecanbe porcinebuccal,sublingual,andintestinalmucosa.PlantaMed.78(3),260–268.
foundintheonlineversion. Smith,C.,2011.TheeffectsofSceletiumtortuosuminaninvivomodelofpsychological
stress.J.Ethnopharmacol.133(1),31–36.
Terburg,D.,Syal,S.,Rosenberger,L.A.,etal.,2013.AcuteeffectsofSceletiumtortuosum
Acknowledgements (Zembrin),adual5-HTreuptakeandPDE4inhibitor,inthehumanamygdalaand
itsconnectiontothehypothalamus.Neuropsychopharmacology38,2708–2716.
Waterhouse,G.,DeWet,G.,Pheiffer,R.,1979.“Cannaplant”section.Simonvander
TheauthorsthankJaredBrodinandBarbaraDavis. Stel’sJourneytoNamaqualandin1685.Human&Rousseau,Capetown.

